Skip to main content
padlock icon - secure page this page is secure

The Effect of an Estrone D-Lactam Steroid Ester Derivative on Breast Cancer Cells and Its Predicted Binding Interactions With the Ligand Binding Domain of Estrogen Receptor-α

Buy Article:

$46.00 + tax (Refund Policy)

In order to further improve the toxicity profile and the anticancer effect of chlorambucil (CBL), we have synthesized a new estrone D-lactam steroidal ester of CBL (ESBL). The aim of this study was to investigate the in vitro activity of ESBL against primary breast carcinoma (BC) cells of operable tumors in comparison with CBL. Cells derived from fresh tumor sections that were obtained from 28 postmenopausal women with ductal BC were treated with CBL and ESBL. Apoptotic cells were distinguished from viable ones with flow cytometric methods. ESBL generated a significantly higher rate of cell apoptosis and cytotoxicity than CBL. ESBL cytotoxic effect demonstrated a significant positive weak to moderate dose-dependent correlation with the ER expression. ESBL produced antineoplastic activity superior to CBL on primary BC tumors in vitro. Moreover, a docking study on the binding interactions of ESBL with the ligand binding domain (LBD) of estrogen receptor-α (ERα) was investigated. ESBL was found to be positioned inside the binding cavity with its steroidal moiety, whereas the alkylating moiety protruded out of receptor's pocket.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Breast cancer; Chlorambucil; Docking; Estrogen receptor; Flow cytometry; Homo-aza-steroid alkylating esters

Document Type: Research Article

Affiliations: 1: 1st Department of Surgery, University of Athens, Laiko General Hospital, Athens, Greece 2: Lab of Medicinal Chemistry, Department of Pharmacy, University of Patras, Patras, Greece, 1st Department of Medical Oncology, “Metaxa” Cancer Hospital, Piraeus, Greece 3: Department of Cell Culture-Molecular Modeling & Drug Design, Symeonidio Research Center, Theagenio Cancer Hospital, Thessaloniki, Greece 4: Department of Pharmacognosy & Chemistry of Natural Products, School of Pharmacy, University of Athens, Athens, Greece 5: Lab of Medicinal Chemistry, Department of Pharmacy, University of Patras, Patras, Greece

Publication date: March 1, 2006

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more